PL2086642T3 - DNaza do leczenia męskiej subpłodności - Google Patents

DNaza do leczenia męskiej subpłodności

Info

Publication number
PL2086642T3
PL2086642T3 PL07827224T PL07827224T PL2086642T3 PL 2086642 T3 PL2086642 T3 PL 2086642T3 PL 07827224 T PL07827224 T PL 07827224T PL 07827224 T PL07827224 T PL 07827224T PL 2086642 T3 PL2086642 T3 PL 2086642T3
Authority
PL
Poland
Prior art keywords
dnase
fertility
treatment
male sub
male
Prior art date
Application number
PL07827224T
Other languages
English (en)
Inventor
Benjamin Bartoov
Ronen Yehuda
Melamed Dobroslav
Original Assignee
Periness Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Periness Ltd filed Critical Periness Ltd
Publication of PL2086642T3 publication Critical patent/PL2086642T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
PL07827224T 2006-10-18 2007-10-18 DNaza do leczenia męskiej subpłodności PL2086642T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85240206P 2006-10-18 2006-10-18
EP20070827224 EP2086642B1 (en) 2006-10-18 2007-10-18 Dnase for the treatment of male sub-fertility
PCT/IL2007/001250 WO2008047364A2 (en) 2006-10-18 2007-10-18 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility

Publications (1)

Publication Number Publication Date
PL2086642T3 true PL2086642T3 (pl) 2015-02-27

Family

ID=39204993

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07827224T PL2086642T3 (pl) 2006-10-18 2007-10-18 DNaza do leczenia męskiej subpłodności

Country Status (13)

Country Link
US (2) US20110033438A1 (pl)
EP (3) EP2416156B1 (pl)
JP (1) JP5323707B2 (pl)
CN (2) CN105664141A (pl)
AU (1) AU2007311444B2 (pl)
BR (1) BRPI0717439A2 (pl)
CA (1) CA2666794C (pl)
DK (1) DK2086642T3 (pl)
ES (1) ES2524458T3 (pl)
PL (1) PL2086642T3 (pl)
PT (1) PT2086642E (pl)
RU (1) RU2009118359A (pl)
WO (1) WO2008047364A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) * 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
EP2095825B8 (en) * 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
JP5092149B2 (ja) * 2008-05-30 2012-12-05 国立大学法人 千葉大学 精子機能の検査方法
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
US20150087610A1 (en) * 2012-03-20 2015-03-26 Monell Chemcial Senses Center Method of Modifying Fertility
MX359291B (es) * 2012-08-03 2018-09-24 Ferring Bv Adn libre de celulas como objetivo terapeutico para la infertilidad femenina y marcador de diagnostico.
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN106715332B (zh) * 2014-07-21 2019-01-29 欧梭莱夫公司 用于治疗不孕症、促进雌性哺乳动物的正常繁殖和生育力及提高辅助生殖技术功效的钨盐
BR112017014433A2 (pt) 2015-01-04 2018-05-15 Protalix Ltd. proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica
US9304003B1 (en) * 2015-03-18 2016-04-05 Microsoft Technology Licensing, Llc Augmented reality navigation
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도
CN105779568B (zh) * 2016-03-16 2019-09-24 四川大学华西第二医院 一种体外获能后精子质量评估的试剂盒及其使用方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2019036719A2 (en) 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY
CN111433605B (zh) 2017-09-18 2023-09-08 圣特萨斯股份公司 用于针对循环无细胞dna纯化血液的方法和装置
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
MX2021004022A (es) 2018-10-08 2021-09-10 Neutrolis Inc Modificacion genetica de enzimas dnasas para elaboracion y terapia.
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
GB2598938A (en) * 2020-09-18 2022-03-23 Provost Fellows Found Scholars & Other Members Board College Holy & Und A method of evaluating sperm health and identifying sperm to be used in assisted reproductive technologies
WO2022249170A1 (en) * 2021-05-24 2022-12-01 Peri-Ness Technologies Ltd Therapeutic regimen with dnase
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8517071D0 (en) * 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4996155A (en) * 1988-03-04 1991-02-26 Mycogen Corporation Bacillus thuringiensis gene encoding a coleopteran-active toxin
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US20010008764A1 (en) * 1989-07-28 2001-07-19 Roy Ax Fertility-related proteins, and methods of use thereof
DE4024530A1 (de) * 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US6251648B1 (en) * 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
GB9826541D0 (en) * 1998-12-02 1999-01-27 King S College London Modulation of sperm function
US20010044937A1 (en) * 1999-12-17 2001-11-22 Gerald Schatten Methods for producing transgenic animals
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
JP2003524646A (ja) * 2000-01-25 2003-08-19 エアロファーム テクノロジー インコーポレイテッド 医薬エアゾール製剤
US6576634B1 (en) 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
CA2415348C (en) * 2000-07-14 2011-07-12 The Arizona Board Of Regents On Behalf Of The University Of Arizona Isolated polynucleotide sequences encoding a fertility associated antigen
EE200300085A (et) * 2000-08-31 2004-12-15 Pfizer Products Inc. Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
DK1549337T3 (en) * 2002-02-18 2014-11-24 Ockham Biotech Ltd COMBINATION OF DNASE I AND GLYCOSAMINOGLYCANES FOR USE IN EXTRACELLULAR DNA CLEARANCE
ES2286201T3 (es) * 2002-12-18 2007-12-01 Coy, Johannes F., Dr. Compuestos y procedimientos para la deteccion de carcinomas y sus lesiones precursoras.
US7118901B2 (en) * 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
JP4417273B2 (ja) * 2004-02-12 2010-02-17 独立行政法人科学技術振興機構 精子活性化剤および精子不活性化剤
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2007131113A2 (en) * 2006-05-03 2007-11-15 Board Of Regents, The University Of Texas System Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury

Also Published As

Publication number Publication date
ES2524458T3 (es) 2014-12-09
AU2007311444A2 (en) 2009-05-28
US20110033438A1 (en) 2011-02-10
CA2666794A1 (en) 2008-04-24
CN105664141A (zh) 2016-06-15
EP2416156B1 (en) 2015-12-30
EP2416156A1 (en) 2012-02-08
WO2008047364A2 (en) 2008-04-24
RU2009118359A (ru) 2010-11-20
CN101563134A (zh) 2009-10-21
CA2666794C (en) 2017-12-12
AU2007311444A1 (en) 2008-04-24
PT2086642E (pt) 2014-09-30
WO2008047364A3 (en) 2008-08-28
BRPI0717439A2 (pt) 2013-11-19
US20130121985A1 (en) 2013-05-16
US9149513B2 (en) 2015-10-06
EP2086642B1 (en) 2014-06-25
DK2086642T3 (da) 2014-09-29
JP2010506903A (ja) 2010-03-04
AU2007311444B2 (en) 2012-11-29
EP2416155A1 (en) 2012-02-08
JP5323707B2 (ja) 2013-10-23
EP2086642A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
PL2086642T3 (pl) DNaza do leczenia męskiej subpłodności
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
GB0620359D0 (en) Medical devices
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL194506A0 (en) Implants for the treatment of dopamine associated states
GB0624874D0 (en) Treatment
EP2324041A4 (en) PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
GB0618930D0 (en) Medical implant
GB0600692D0 (en) Well treatment
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA200806505B (en) Treatment of HIV
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0617134D0 (en) Medical devices
GB0604460D0 (en) Treatment
EP2077797A4 (en) IMPLANTABLE DEVICES AND METHODS OF FORMATION THEREOF
IL197486A0 (en) Novel method of treatment of male sub-fertility
GB0602857D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
IL198175A0 (en) Method and pharamcological composition for the diagnosis and treatment of male sub-fertility
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0600817D0 (en) Medical treatment
HK1122032A (en) Benzoisoindole derivatives for the treatment of pain